Assessment of Insulin Infusion Requirements in COVID-19-Infected Patients With Diabetic Ketoacidosis |
| |
| Authors: | Daniela Farzadfar Caitlyn A. Gordon Keith P. Falsetta Tori Calder Adey Tsegaye Nina Kohn Rifka Schulman-Rosenbaum |
| |
| Affiliation: | 1. Department of Pharmacy, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, New York;2. Division of Endocrinology, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, New York;3. Division of Pulmonary, Critical Care, and Sleep Medicine, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, New York;4. Feinstein Institutes for Medical Research, Northwell Health, Great Neck, New York |
| |
| Abstract: | Background/ObjectiveCoronavirus disease 2019 (COVID-19) is thought to contribute to diabetic ketoacidosis (DKA) and worse outcomes in patients with diabetes. This study compared the cumulative insulin dose required to achieve DKA resolution in the intensive care unit among patients with type 2 diabetes and COVID-19 infection versus without COVID-19 infection.MethodsThis retrospective cohort study evaluated 100 patients—50 patients with COVID-19 in cohort 1 and 50 patients without COVID-19 in cohort 2—treated with insulin infusions for DKA at a tertiary care teaching hospital. The primary outcome was to compare the cumulative insulin dose required to achieve DKA resolution in each cohort. The secondary outcomes included time to DKA resolution, mean insulin infusion rate, and mean weight-based cumulative insulin infusion dose required to achieve DKA resolution. All endpoints were adjusted for confounders.ResultsThe mean cumulative insulin dose was 190.3 units in cohort 1 versus 116.4 units in cohort 2 (P = .0038). Patients receiving steroids had a mean time to DKA resolution of 35.9 hours in cohort 1 versus 15.6 hours in cohort 2 (P = .0014). In cohort 1 versus cohort 2, the mean insulin infusion rate was 7.1 units/hour versus 5.3 units/hour (P = .0025), whereas the mean weight-based cumulative insulin infusion dose was 2.1 units/kg versus 1.5 units/kg (P = .0437), respectively.ConclusionCOVID-19-infected patients required a significantly larger cumulative insulin dose, longer time to DKA resolution, higher insulin infusion rate, and higher weight-based insulin infusion dose to achieve DKA resolution versus non–COVID-19-infected patients with type 2 diabetes. |
| |
| Keywords: | diabetic ketoacidosis (DKA) insulin infusion clinical requirements coronavirus disease 2019 (COVID-19) type 2 diabetes AG" },{" #name" :" keyword" ," $" :{" id" :" kwrd0040" }," $$" :[{" #name" :" text" ," _" :" anion gap ANOVA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0050" }," $$" :[{" #name" :" text" ," _" :" analysis of variance BG" },{" #name" :" keyword" ," $" :{" id" :" kwrd0060" }," $$" :[{" #name" :" text" ," _" :" blood glucose BMI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0070" }," $$" :[{" #name" :" text" ," _" :" body mass index CI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0080" }," $$" :[{" #name" :" text" ," _" :" confidence interval COVID-19" },{" #name" :" keyword" ," $" :{" id" :" kwrd0090" }," $$" :[{" #name" :" text" ," _" :" coronavirus disease 2019 DKA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0100" }," $$" :[{" #name" :" text" ," _" :" diabetic ketoacidosis ICU" },{" #name" :" keyword" ," $" :{" id" :" kwrd0110" }," $$" :[{" #name" :" text" ," _" :" intensive care unit LIJMC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0120" }," $$" :[{" #name" :" text" ," _" :" Long Island Jewish Medical Center LOS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0130" }," $$" :[{" #name" :" text" ," _" :" length of stay |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
